Last updated: Jul 11, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT06066138 | 1 | A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | PD-L1 -- immune checkpoint inhibitor (atezolizumab) |
| NCT06246916 | 3 | A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | LAG-3 + PD-1 -- bispecific antibody (fianlimab + cemiplimab; relatlimab + nivolumab) |
| NCT06910657 | 1 | IDOV-Immune for Advanced Solid Tumors | Oncolytic vaccinia virus -- oncolytic virus therapy (IDOV-Immune) |
| NCT07341737 | 1, 2 | SL-28 for Advanced Solid Tumours | Unknown mechanism |
| NCT06466434 | 2 | Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma | Unknown mechanism |
| Sponsor | Recruiting trials |
|---|---|
| M.D. Anderson Cancer Center | 17 |
| Vastra Gotaland Region | 7 |
| H. Lee Moffitt Cancer Center and Research Institute | 7 |
| National Cancer Institute (NCI) | 6 |
| Xijing Hospital | 5 |
Countries/regions with the most active trial sites for melanoma. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Aug 31, 2026 | NCT07444606 | Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases | Oncolytic adenovirus -- oncolytic viral therapy (DNX-2401) |
| Aug 31, 2026 | NCT07414979 | Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma | Tumor antigens -- adoptive CD8+ antigen-specific T cell therapy |
| Aug 1, 2026 | NCT07581509 | Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma | PD-1 -- immune checkpoint inhibition (monoclonal antibody) |
| Aug 1, 2026 | NCT07694414 | Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse Events | CD20 -- monoclonal antibody (RTX) |
| Jul 31, 2026 | NCT07631325 | Axelopran in Patients With Anti-PD-1 Refractory Metastatic or Locoregionally Unresectable Cutaneous Melanoma | Opioid receptors -- antagonist (small molecule) |
| Jul 2026 | NCT07281924 | Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis | PD-1 + LAG-3 -- bispecific antibody (Nivolumab and Relatlimab); Melphalan -- alkylating agent |
| Jul 2026 | NCT07615881 | Comparing Intravenous or Intradermal Administration of Anti-CTLA-4 in Combination With Anti-PD1 Treatment in Patients With Melanoma | CTLA-4 + PD-1 -- immune checkpoint blockade (monoclonal antibodies) |
| Jun 30, 2026 | NCT07518043 | A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors | PD-1 -- immune checkpoint inhibitor biosimilar (monoclonal antibody) |
You've seen the melanoma landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.